101 related articles for article (PubMed ID: 1985738)
1. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations.
Tafuri A; Meyers J; Lee BJ; Andreeff M
Cancer; 1991 Jan; 67(2):449-54. PubMed ID: 1985738
[TBL] [Abstract][Full Text] [Related]
2. Biclonal and hypodiploid multiple myeloma.
Smith L; Barlogie B; Alexanian R
Am J Med; 1986 May; 80(5):841-3. PubMed ID: 3706371
[TBL] [Abstract][Full Text] [Related]
3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
4. DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation.
Suarez C; Miller DR; Steinherz PG; Melamed MM; Andreeff M
Br J Haematol; 1985 Aug; 60(4):677-86. PubMed ID: 3861195
[TBL] [Abstract][Full Text] [Related]
5. Characterization of hematologic malignancies by flow cytometry.
Barlogie B; Latreille J; Freireich EJ; Fu CT; Mellard D; Meistrich M; Andreeff M
Blood Cells; 1980; 6(4):719-44. PubMed ID: 7008871
[TBL] [Abstract][Full Text] [Related]
6. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
[TBL] [Abstract][Full Text] [Related]
7. DNA content of human myeloma cells.
Lewensohn R; Tribukait B; Hansson J
Eur J Cancer Clin Oncol; 1983 Jan; 19(1):59-63. PubMed ID: 6682777
[TBL] [Abstract][Full Text] [Related]
8. Biology and therapy of multiple myeloma.
Barlogie B; Alexanian R
Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
[TBL] [Abstract][Full Text] [Related]
9. [Proliferative activity assessed on the basis of DNA ploidy patterns in primary lung cancer].
Yamaoka N; Tagawa Y; Miyashita K; Ayabe H; Kawahara K; Uchiyama Y; Tomita M
Nihon Geka Gakkai Zasshi; 1991 May; 92(5):598-602. PubMed ID: 1875901
[TBL] [Abstract][Full Text] [Related]
10. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.
Samson D; Gaminara E; Newland A; Van de Pette J; Kearney J; McCarthy D; Joyner M; Aston L; Mitchell T; Hamon M
Lancet; 1989 Oct; 2(8668):882-5. PubMed ID: 2571813
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.
Epstein J; Xiao HQ; Oba BK
Blood; 1989 Aug; 74(3):913-7. PubMed ID: 2568864
[TBL] [Abstract][Full Text] [Related]
12. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
[TBL] [Abstract][Full Text] [Related]
13. Dual parameter analysis of myeloma cells by flow cytometry. DNA content of cells containing monotypic cytoplasmic immunoglobulin.
Chan CS; Wormsley SB; Peter JB; Schechter GP
Am J Clin Pathol; 1989 Jan; 91(1):12-7. PubMed ID: 2910012
[TBL] [Abstract][Full Text] [Related]
14. Therapy of primary resistant and relapsed multiple myeloma.
Barlogie B; Alexanian R
Onkologie; 1986 Aug; 9(4):210-4. PubMed ID: 3531948
[TBL] [Abstract][Full Text] [Related]
15. High-dose glucocorticoid treatment of resistant myeloma.
Alexanian R; Barlogie B; Dixon D
Ann Intern Med; 1986 Jul; 105(1):8-11. PubMed ID: 3717812
[TBL] [Abstract][Full Text] [Related]
16. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
[TBL] [Abstract][Full Text] [Related]
19. [Long-term survival in terms of DNA-RNA contents in breast cancer].
Hara S; Kondo M; Tagawa Y; Itoyanagi N; Kishimoto K; Matuo S; Akamine S; Takahashi T; Oka T; Ayabe H
Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():422-5. PubMed ID: 9589046
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
